SELLAS Life Sciences (SLS) Gains from Investment Securities (2010 - 2023)
SELLAS Life Sciences (SLS) reported Gains from Investment Securities of $368000.0 for Q4 2023, down 18.04% quarter-over-quarter from $449000.0 in Q1 2022.
SELLAS Life Sciences (SLS) Gains from Investment Securities (2010 - 2023) Analysis & Trends
SELLAS Life Sciences (SLS) has 10 years of Gains from Investment Securities data on file, last reported at $368000.0 in Q4 2023.
- Gains from Investment Securities for Q4 2023 came in at $368000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $368000.0 (down 18.04% YoY), and the FY2025 annual result was $526000.0, up 721.88% from the prior year.
- Gains from Investment Securities slipped to $368000.0 in Q4 2023 per SLS's latest filing, from $449000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $853000.0 in Q2 2020 and troughed at -$1000.0 in Q4 2019.
- A 4-year average of $390333.3 and a median of $408500.0 in 2022 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 55.09% in 2020 and fell as far as 55.09% in 2020.
- A 4-year view of Gains from Investment Securities shows it stood at -$1000.0 in 2019, then jumped by 85400.0% to $853000.0 in 2020, then sank by 47.36% to $449000.0 in 2022, then slipped by 18.04% to $368000.0 in 2023.
- Business Quant data shows SLS's Gains from Investment Securities at $368000.0 in Q4 2023, $449000.0 in Q1 2022, and $853000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 368,000.00 |
| Dec 31, 2023 | 368,000.00 |
| Mar 31, 2022 | 449,000.00 |
| Mar 31, 2022 | 449,000.00 |
| Jun 30, 2020 | 853,000.00 |
| Jun 30, 2020 | 853,000.00 |
| Mar 31, 2020 | 123,000.00 |
| Mar 31, 2020 | 123,000.00 |
| Dec 31, 2019 | -1,000.00 |
| Dec 31, 2019 | -1,000.00 |
| Jun 30, 2019 | 550,000.00 |
| Jun 30, 2019 | 550,000.00 |
| Dec 31, 2017 | 10,000.00 |
| Dec 31, 2017 | 10,000.00 |
| Dec 31, 2016 | 55,000.00 |
| Dec 31, 2016 | 55,000.00 |
| Mar 31, 2013 | 393,101.00 |
| Mar 31, 2013 | 393,101.00 |
| Dec 31, 2012 | 264,816.00 |
| Dec 31, 2012 | 264,816.00 |